Viking Therapeutics, Inc. (VKTX)

Over the past six months, Viking Therapeutics reported its Fourth Quarter and Year-End 2025 financial results in February 2026 and First Quarter 2026 financial results on April 29, 2026. The stock experienced a decline of over 3% on the day of its Q1 2026 earnings report, and was down over 14% in 2026 despite encouraging progress in its clinical trials. The company has also announced participation in various investor conferences. Positive news included the completion of enrollment in the Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 in obesity. Data from a Phase 2 VENTURE-Oral trial of VK2735 and participant characteristics from the Phase 3 VANQUISH-1 trial were presented at the European Congress on Obesity (ECO) 2026 in May 2026. Analysts have a consensus price target for VKTX that suggests a potential return of over 200%.

As a clinical-stage biopharmaceutical company, Viking Therapeutics does not have traditional demand seasonality. The company's value and market sentiment are heavily influenced by the progress and results of its clinical trials, regulatory milestones, and investor conferences. The primary drivers of interest and "demand" for VKTX stock are tied to its drug development pipeline, particularly the advancement of VK2735 in obesity.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Their pipeline includes VK2735, a dual GLP-1 and GIP receptor agonist for obesity in Phase 3 trials; VK2809, an oral thyroid hormone receptor beta agonist for lipid and metabolic disorders; VK5211, an oral selective androgen receptor modulator; and VK0214, an oral thyroid hormone receptor beta agonist for adrenomyeloneuronopathy.

Viking Therapeutics is headquartered in San Diego, California, and its stock is listed on multiple international exchanges, including NASDAQ, Deutsche Boerse AG, London Stock Exchange, and Borsa Italiana.

Viking Therapeutics maintains a generally positive brand reputation, reflected by a consensus "Moderate Buy" rating from analysts. The company's average rating score is 2.85, based on 3 strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating. MarketBeat's MarketRank™ scored Viking Therapeutics higher than 72% of evaluated companies, ranking it 190th out of 857 stocks in the medical sector. The company's ongoing progress in clinical trials contributes to its reputation as a promising player.

Viking Therapeutics has a diverse ownership structure, with institutional investors holding a significant portion of the stock. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and Fmr Llc. Approximately 32.25% of the company's stock is owned by Institutional Investors, 2.88% by Insiders, and 64.87% by Public Companies and Individual Investors. In the past three months, insiders have bought more company stock than they have sold, with $149,912.00 in purchases and no sales.